ArticleFuture oncology (London, England)2026
TroFuse-011 study design: sacituzumab tirumotecan with or without pembrolizumab for advanced triple-negative breast cancer with PD-L1 CPS <10.
Hope S Rugo et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.